Results 201 to 210 of about 74,284 (255)
Rational payload selection enables high antitumoral efficacy of an anti-EGFR antibody-drug conjugate against ovarian tumors. [PDF]
NeoplasiaAlmaraz-Postigo S +2 more
europepmc +1 more source
Population-Based Modeling to Predict Human PK/PD of TAK-500, an Anti-CCR2 Antibody-Drug Conjugate for First-in-Human Study in Cancer Patients. [PDF]
Clin Transl SciSaravanakumar A +8 more
europepmc +1 more source
Can Epithelial-Myoepithelial Carcinoma of the Breast Benefit from TROP2 Antibody-Drug Conjugate? [PDF]
Onco Targets TherZhao Q +5 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Current Opinion in Oncology, 2014
Antibody conjugates are a diverse complex class of therapeutics, consisting of a potent cytotoxic agent linked covalently to an antibody or antibody fragment directed toward a specific cell surface target expressed by tumor cells or an extracellular target, that are having impact in the clinic.
BATT DAVID BRYANT +7 more
+22 more sources
Antibody conjugates are a diverse complex class of therapeutics, consisting of a potent cytotoxic agent linked covalently to an antibody or antibody fragment directed toward a specific cell surface target expressed by tumor cells or an extracellular target, that are having impact in the clinic.
BATT DAVID BRYANT +7 more
+22 more sources
Biotechnology Letters, 2016
Antibody drug conjugates (ADCs) have emerged as a viable option in targeted delivery of highly potent cytotoxic drugs in treatment of solid tumors. At the time of writing, only two ADCs have received regulatory approval with >40 others in clinical development. The first generation ADCs suffered from a lack of specificity in amino acid site-conjugations,
ABRAMS TINYA +8 more
openaire +7 more sources
Antibody drug conjugates (ADCs) have emerged as a viable option in targeted delivery of highly potent cytotoxic drugs in treatment of solid tumors. At the time of writing, only two ADCs have received regulatory approval with >40 others in clinical development. The first generation ADCs suffered from a lack of specificity in amino acid site-conjugations,
ABRAMS TINYA +8 more
openaire +7 more sources
Antibody-Conjugated Drug Assay for Protease-Cleavable Antibody–Drug Conjugates
Bioanalysis, 2015Antibody-drug conjugates (ADCs) require multiple assays to characterize their PK. These assays can separately evaluate the ADC by quantifying the antibody or the conjugated drug and may give different answers due to assay measurement differences, heterogeneous nature of ADCs and potential biotransformations that occur in vivo.We present a new version ...
Russell J, Sanderson +6 more
openaire +2 more sources
Antibody–drug conjugates for cancer
The Lancet, 2019Antibody-drug conjugates (ADCs) are immunoconjugates comprised of a monoclonal antibody tethered to a cytotoxic drug (known as the payload) via a chemical linker. The ADC is designed to selectively deliver the ultratoxic payload directly to the target cancer cells.
Cindy H, Chau +2 more
openaire +2 more sources
Antibody–Drug Conjugates for Immunology
Journal of Medicinal Chemistry, 2022The application of antibody-drug conjugates (ADCs) to fields outside of oncology is increasing but is still relatively uncommon. A recent publication describes the conjugation of glucocorticoid receptor modulators to antibodies as a means of improving the separation between desired anti-inflammatory activity and unwanted systemic side effects.
openaire +2 more sources
The Promise of Antibody–Drug Conjugates
New England Journal of Medicine, 2012The promise of antibody–drug conjugates (ADCs) is the specific targeting of highly potent cytotoxic agents to malignant disease without adversely affecting normal tissues. We may be on the verge of fulfilling that promise. This moment has been more than 25 years in the making and has required technology development in every facet of the conception and ...
Beverly A, Teicher, James H, Doroshow
openaire +2 more sources
Antibody–Drug Conjugate Payloads
2013Toxin payloads, or drugs, are the crucial components of therapeutic antibody-drug conjugates (ADCs). This review will give an introduction on the requirements that make a toxic compound suitable to be used in an antitumoral ADC and will summarize the structural and mechanistic features of four drug families that yielded promising results in preclinical
Jan, Anderl +3 more
openaire +2 more sources